Celator(R) Pharmaceuticals Presents Interim Data From Phase 2 Study Of CPX-351 In Newly Diagnosed AML At American Society Of Hematology Meeting
Links shared publicly online about this topic.
- 1,545total visits
Celator(R) Pharmaceuticals Presents Interim Data From Phase 2 Study Of CPX-351 In Newly Diagnosed AML At American Society Of Hematology Meeting
Celator Pharmaceuticals announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection
View full resource at medicalnewstoday.com
Tags: Leukemia, Acute Myelogenous Leukemia, Pharma, Phase 2 Clinical Trial, Clinical Trial, Safety
Most Recently Shared on December 8, 2009 at 5:36 pm By:
Celator(R) Pharmaceuticals Presents Interim Data From Phase 2 Study Of CPX-351 In Newly Diagnosed AML At American S... http://bit.ly/5umdYQ
Advertisement
